.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Farmers Insurance
Mallinckrodt
US Department of Justice
McKinsey
Accenture
Colorcon
US Army
AstraZeneca
Express Scripts

Generated: December 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,173,037

« Back to Dashboard

Claims for Patent: 7,173,037

Title:Carbamate-substituted pyrazolopyridines
Abstract: The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.
Inventor(s): Alonso-Alija; Cristina (Haan, DE), Bischoff; Erwin (Wuppertal, DE), Munter; Klaus (Wulfrath, DE), Stasch; Johannes-Peter (Solingen, DE), Stahl; Elke (Gladbach, DE), Weigand; Stefan (Wuppertal, DE), Feurer; Achim (Wilhelmsfeld, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/513,869
Patent Claims: 1. A compound of the formula (I) ##STR00030## in which R.sup.1 is --NR.sup.3C(.dbd.O)OR.sup.4, R.sup.2 is hydrogen or NH.sub.2, R.sup.3 is hydrogen or (C.sub.1 C.sub.4)-alkyl, R.sup.4 is (C.sub.1 C.sub.6)-alkyl, or a salt or hydrate thereof.

2. The compound of claim 1, in which R.sup.1 is --NR.sup.3C(.dbd.O)OR.sup.4, R.sup.2 is hydrogen or NH.sub.2, R.sup.3 is (C.sub.1 C.sub.4)-alkyl, R.sup.4 is (C.sub.1 C.sub.4)-alkyl, or a salt or hydrate thereof.

3. The compound of claim 1, in which R.sup.1 is --NR.sup.3C(.dbd.O)OR.sup.4, R.sup.2 is NH.sub.2, R.sup.3 is methyl or ethyl, R.sup.4 is methyl, ethyl or isopropyl, or a salt or hydrate thereof.

4. The compound of claim 1 having the following structure: methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrim- idinyl(methyl)carbamate ##STR00031## or a salt or hydrate thereof.

5. The compound of claim 1, wherein said compound is methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrim- idinylcarbamate: ##STR00032## or a salt or hydrate thereof.

6. A process for the preparation of compounds of the formula (I) as defined in claim 1, characterized in that either [A] a compound of the formula (Ia) ##STR00033## in which R.sup.4 is as defined in claim 1, is reacted with a compound of the formula (II) R.sup.3--X.sup.1 (II), in which R.sup.3 is as defined in claim 1, and X.sup.1 is a leaving group, or [B] the compound of the formula (III) ##STR00034## is reacted with a compound of the formula (IV) ##STR00035## in which R.sup.4 is as defined in claim 1, or [C] the compound of the formula (V) ##STR00036## is reacted with a compound of the formula (VI) ##STR00037## in which R.sup.3 and R.sup.4 are as defined in claim 1, to give a compound of the formula (Ib) ##STR00038## in which R.sup.3 and R.sup.4 are as defined in claim 1.

7. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1, and at least one further excipient.

8. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1 in combination with at least one organic nitrate or NO donor.

9. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1 in combination with at least one compound which inhibits the breakdown of cyclic guanosine monophosphate (cGMP).

10. A method for the treatment of hypertension, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

11. A method for the treatment of sexual dysfunction, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

12. The method of claim 10 or 11, where compounds of the formula (I) as defined in claim 1 are employed in combination with at least one organic nitrate or NO donor or in combination with at least one compound which inhibits the breakdown of cyclic guanosine monophosphate (cGMP).

13. The method of claim 11, wherein the sexual dysfunction is erectile dysfunction or female sexual dysfunction.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Harvard Business School
Deloitte
Chinese Patent Office
Colorcon
Johnson and Johnson
Teva
Cerilliant
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot